SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

002864

CNE1000032C9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
30.24 ^CNY	+2.34%		+3.70%	-21.43%

26/04	Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023	CI
25/04	Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023

April 27, 2024 at 01:06 am IST

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd. announced on 26 April 2024 the profit distribution proposal for 2023: Cash dividend (tax included) of CNY 2.20000000 per 10 shares.

Latest news about Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023	27/04	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's Equity Buyback Plan announced on March 14, 2024.	02/04	CI
Panlong Pharmaceutical Plans 20 Million Yuan Share Buyback	14/03	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announces an Equity Buyback for CNY 20 million worth of its shares.	13/03	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd authorizes a Buyback Plan.	13/03	CI
Panlong Pharmaceutical Gets Sanitary License	15/01	MT
Panlong Pharmaceutical Gets Certificate for Shaanxi Good Trademark	27/12	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it has received CNY 301.999975 million in funding	09/23/09	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Panlong Pharma Completes Registration of New Medical Clinic	09/23/09	MT
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd. Approves Cash Dividend for 2022, Payable on May 31, 2023	23/23/23	CI
Chinese Shares Retreat; Panlong Pharma Falls 7% on 302 Million Yuan Share Sale	09/23/09	MT
Shaanxi Panlong Pharma Selling 302 Million Yuan Shares to Fund New Projects	09/23/09	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd. Proposes Final Cash Dividend for 2022	25/23/25	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	06/23/06	CI
Panlong Pharma Gets US Patent for Coronavirus Protease Inhibitor	04/23/04	MT
Shaanxi Panlong Pharma Raising 302 Million Yuan From Share Sale	28/23/28	MT
Shaanxi Panlong Pharma to Pay Interest on 276 Million Yuan Bonds	24/23/24	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it expects to receive CNY 302 million in funding	28/22/28	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments	14/22/14	CI

Chart Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Duration

Period

Chart Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

More charts

SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent drugs. The Company's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The Company also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The Company is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The Company distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

21/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

30.24 CNY

Average target price

41.72 CNY

Spread / Average Target

+37.96%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD	-21.43%	430M
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals